5-(4-methyl-1,4-diazepan-1-yl)-2-(pyrrolidin-3-ylmethyl)pyridazin-3-one;bis(2,2,2-trifluoroacetic acid)
C19H27F6N5O5 — CID 154891674
Data last refreshed: (MolForge compound catalog, from PubChem)
About 5-(4-methyl-1,4-diazepan-1-yl)-2-(pyrrolidin-3-ylmethyl)pyridazin-3-one;bis(2,2,2-trifluoroacetic acid)
5-(4-methyl-1,4-diazepan-1-yl)-2-(pyrrolidin-3-ylmethyl)pyridazin-3-one;bis(2,2,2-trifluoroacetic acid) (PubChem CID 154891674) has the molecular formula C19H27F6N5O5 and a molecular weight of 519.44 g/mol. Its IUPAC name is 5-(4-methyl-1,4-diazepan-1-yl)-2-(pyrrolidin-3-ylmethyl)pyridazin-3-one;bis(2,2,2-trifluoroacetic acid).
Molecular Properties
| Compound Name | 5-(4-methyl-1,4-diazepan-1-yl)-2-(pyrrolidin-3-ylmethyl)pyridazin-3-one;bis(2,2,2-trifluoroacetic acid) |
|---|---|
| PubChem CID | 154891674 |
| Molecular Formula | C19H27F6N5O5 |
| Molecular Weight | 519.44 g/mol |
| Exact Mass | 519.19 |
| IUPAC Name | 5-(4-methyl-1,4-diazepan-1-yl)-2-(pyrrolidin-3-ylmethyl)pyridazin-3-one;bis(2,2,2-trifluoroacetic acid) |
| SMILES | CN1CCCN(c2cnn(CC3CCNC3)c(=O)c2)CC1.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F |
| InChI | InChI=1S/C15H25N5O.2C2HF3O2/c1-18-5-2-6-19(8-7-18)14-9-15(21)20(17-11-14)12-13-3-4-16-10-13;2*3-2(4,5)1(6)7/h9,11,13,16H,2-8,10,12H2,1H3;2*(H,6,7) |
| InChIKey | AHQUEAMUQFRSJP-UHFFFAOYSA-N |
| XLogP | 1.26 |
| TPSA | 128.00 Ų |
| H-Bond Donors | 3 |
| H-Bond Acceptors | 8 |
| Rotatable Bonds | 3 |
| Heavy Atoms | 35 |
| Complexity | — |
Lipinski Rule of Five
1 violation
| Rule | Value |
|---|---|
| MW ≤ 500 | 519.44 |
| LogP ≤ 5 | 1.26 |
| H-Bond Donors ≤ 5 | 3 |
| H-Bond Acceptors ≤ 10 | 8 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 154891674 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.